Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport and resistance to the drug in HEK-293 cells

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 232-237

  Eddabra, Lahcen ^a   Wenner, Thomas ^b   El Btaouri, Hassan ^a   Baranek, Thomas ^c   Madoulet, Claudie ^a   Cornillet Lefebvre, Pascale ^c   Hamid, Morjani ^a  

^a UFR Sciences Exactes et Naturelles   (France)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

ABCG2 BCRP; Etoposide transport; Mutation; Resistance

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ETOPOSIDE; FUMITREMORGIN C; MESSENGER RNA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NOVOBIOCIN;

ABCG2 GENE; ARTICLE; BIOACCUMULATION; CELL STRAIN HEK293; CODON; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG UPTAKE; EMBRYO; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARGININE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FLOW CYTOMETRY; GLYCINE; HEK293 CELLS; HUMANS; NEOPLASM PROTEINS; POINT MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84855288472     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1468     Document Type: Article

References (25)

1. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993. (Pubitemid 23237876)
2. Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302, 2000. (Pubitemid 30662093)
3. Litman T, Druley TE, Stein WD and Bates SE: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959, 2001. (Pubitemid 32652819)
4. Doyle LA and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358, 2003. (Pubitemid 37487163)
5. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS and Bates SE: Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89: 1971-1978, 2003. (Pubitemid 37533279)
6. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD and Schneider E: Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 60: 3514-3521, 2000. (Pubitemid 30482171)
7. Allen JD, Brinkhuis RF, Wijnholds J and Schinkel AH: The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59: 4237-4241, 1999. (Pubitemid 29418735)
8. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O and Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 63: 1339-1344, 2003. (Pubitemid 36348714)
9. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M and Bates SE: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61: 6635-6639, 2001. (Pubitemid 32896477)
10. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T and Bates SE: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59: 8-13, 1999. (Pubitemid 29062946)
11. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H and Nishimura S: Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 61: 2827-2832, 2001. (Pubitemid 32691919)
12. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE and Kruh GD: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63: 4048-4054, 2003. (Pubitemid 36917926)
13. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM and Jansen G: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59: 2532-2535, 1999. (Pubitemid 29269093)
14. Lossos IS, Czerwinski DK, Wechser MA and Levy R: Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia 17: 789-795, 2003. (Pubitemid 36519378)
15. Ginzinger DG: Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 30: 503-512, 2002.
16. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH and Bates SE: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011-2021, 2000. (Pubitemid 30386505)
17. Schneider E, Horton JK, Yang CH, Nakagawa M and Cowan KH: Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54: 152-158, 1994. (Pubitemid 24042102)
18. Yang CH, Chen YC and Kuo ML: Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. Anticancer Res 23: 2519-2523, 2003. (Pubitemid 36897122)
19. Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD and Kohno S: Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 108: 146-151, 2004. (Pubitemid 37444457)
20. Rabindran SK, Ross DD, Doyle LA, Yang W and Greenberger LM: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60: 47-50, 2000. (Pubitemid 30058728)
21. Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE and Assaraf YG: ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 65: 8414-8422, 2005. (Pubitemid 41330608)
22. Allen JD, Jackson SC and Schinkel AH: A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res 62: 2294-2299, 2002. (Pubitemid 34411707)
23. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J and Schinkel AH: Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60: 5761-5766, 2000.
24. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D and Ross DD: Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 9: 3320-3328, 2003. (Pubitemid 37082726)
25. Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD and Baer MR: Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia 18: 1252-1257, 2004. (Pubitemid 39023136)